Dr Shengwei Li | Computer-Assisted Surgical Planning | Best Researcher Award

Dr Shengwei Li | Computer-Assisted Surgical Planning | Best Researcher Award

Peking Union Medical College | China

AUTHOR PROFILE

Scopus

🎓EARLY ACADEMIC PURSUITS 

Shengwei Li graduated from the prestigious Top Pilot Class at Southeast University in 2021. He then embarked on a promising academic career as a doctoral student at Peking Union Medical College, starting in 2022. His foundational studies laid a strong groundwork for his future contributions in the field of interventional oncology. Shengwei has gained valuable experience, particularly in the clinical setting of Zhongda Hospital, where he worked for three years.

🏥PROFESSIONAL ENDEAVORS 

Shengwei’s professional experience specializes in the field of interventional oncology, with a focus on treating malignant tumors. His expertise shines in managing complex cases such as unresectable hepatocellular carcinoma and early-stage lung cancer. His clinical acumen is further enriched through his active participation in several clinical trials, including multi-center randomized controlled trials, all of which contribute to cutting-edge oncology treatments.

🧑‍🔬CONTRIBUTIONS AND RESEARCH FOCUS ON COMPUTER-ASSISTED SURGICAL PLANNING

Shengwei’s research efforts are centered on computer-assisted surgical planning, a field where he has made significant advancements. His major contributions include the development of deep learning-based algorithms that assist in dose calculation for 125I seed-loaded stents and automated image segmentation for liver and vascular systems. These innovations directly improve preoperative planning and surgical outcomes for hepatocellular carcinoma (HCC). Additionally, he has introduced an automatic planning system for CT-guided percutaneous liver tumor ablation, which promises to make treatment planning more efficient for healthcare professionals.

🔬IMPACT AND INFLUENCE 

His published works—five research articles in indexed journals—are primarily focused on improving treatments for unresectable HCC. Shengwei’s groundbreaking research on deep learning and medical algorithms is expected to significantly impact the field of interventional oncology, particularly for hard-to-treat liver cancers. His innovations aim to increase the accuracy and effectiveness of tumor ablation procedures, ultimately benefiting patients and advancing the field of oncology.

📚ACADEMIC CITES AND CREDENTIALS 

Shengwei’s research has garnered recognition within the academic community, reflected by his citation index of 2 and the growing influence of his published works. He has completed 3 research projects and holds 3 patents under process, marking his commitment to innovation. His work has been published in 5 indexed journals, and his ongoing efforts ensure that he continues contributing to the field of medical research and technology.

🔮LEGACY AND FUTURE CONTRIBUTIONS 

Looking ahead, Shengwei Li’s work promises to bridge the gap between clinical practice and technological innovation. His vision of integrating advanced computational techniques with interventional oncology has the potential to transform the way complex cancers are treated. His ongoing research will likely continue to influence future medical practices and technologies, making him a promising figure in both medicine and engineering.

CONCLUSION

Shengwei Li is a promising and dedicated researcher whose work in interventional oncology and computer-assisted surgical planning is making significant strides in the treatment of complex cancers like unresectable hepatocellular carcinoma. His innovative approach, combining deep learning algorithms with clinical practice, highlights his potential to revolutionize cancer treatments. With multiple patents in progress and several impactful research publications, he is well-positioned to contribute further to the advancement of medical science. Shengwei’s interdisciplinary expertise and dedication make him a deserving candidate for the Best Researcher Award.

📊🔬NOTABLE PUBLICATION:

    • Automated segmentation of liver and hepatic vessels on portal venous phase computed tomography images using a deep learning algorithm
      • Authors: Li, S., Li, X.-G., Zhou, F., Peng, J., Li, B.
      • Journal: Journal of Applied Clinical Medical Physics
      • Year: 2024

     

    • Acute-phase plasma proteomics of rabbit lung VX2 tumors treated by image-guided microwave ablation
      • Authors: Cheng, L., Peng, J.-Z., Li, S.-W., Bie, Z.-X., Li, X.-G.
      • Journal: Frontiers in Oncology
      • Year: 2024

Prof. Yibin Feng | Liver Cancer | Lifetime Achievement Award

Prof. Yibin Feng | Liver Cancer | Lifetime Achievement Award

The University of Hong Kong | Hong Kong

AUTHOR PROFILE

Scopus

📚 EARLY ACADEMIC PURSUITS 

Professor Yibin Feng began his academic journey with a focus on traditional medicine and its applications in modern healthcare. His early studies laid a strong foundation in the integration of ancient practices with contemporary scientific research. His education likely included rigorous training in both the theoretical and practical aspects of herbal medicine, setting the stage for his future research.

🌟 PROFESSIONAL ENDEAVORS 

Currently, Professor Feng is associated with The University of Hong Kong, where he specializes in liver cancer treatment using Chinese herbal formulas. His professional role involves leading research projects, mentoring students, and collaborating with other experts in the field to advance the understanding and application of traditional Chinese medicine in oncology.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON LIVER CANCER

Professor Feng’s research primarily concentrates on leveraging Chinese herbal formulas for treating liver cancer. His work explores how traditional remedies can be integrated into modern cancer treatments, aiming to enhance therapeutic outcomes and improve patient quality of life. His contributions include:

  • Investigating the efficacy of herbal formulas in liver cancer treatment.
  • Conducting clinical trials to validate the therapeutic potential of these traditional remedies.
  • Exploring the mechanisms through which these herbal treatments impact cancer cells and patient health.

🌍 IMPACT AND INFLUENCE

Professor Feng’s research has significantly influenced the field of integrative oncology. By bridging traditional Chinese medicine with modern cancer therapies, his work has opened new avenues for treatment strategies that blend ancient wisdom with cutting-edge science. His influence extends through:

  • Enhanced understanding of herbal medicine’s role in cancer treatment.
  • Development of new therapeutic approaches incorporating traditional remedies.
  • Increased acceptance and integration of alternative medicine in mainstream cancer care.

📈 ACADEMIC CITES 

Professor Feng’s research is well-cited within the academic community, reflecting the impact and importance of his work. His publications contribute valuable insights into the application of herbal medicine in cancer treatment, and his findings are referenced by researchers and practitioners seeking to explore or validate similar approaches.

🏆 LEGACY AND FUTURE CONTRIBUTIONS 

Professor Feng’s legacy is defined by his dedication to merging traditional and modern medical practices. His future contributions are expected to further advance the integration of Chinese herbal medicine into contemporary oncology, potentially leading to innovative treatments and improved patient outcomes. His ongoing research and collaborations will likely continue to shape the field and inspire future scholars and practitioners.

🌟 CONCLUSION 

Professor Yibin Feng’s work exemplifies the successful integration of traditional Chinese herbal medicine with modern cancer treatment methodologies. His early academic pursuits laid a robust foundation for his current research, which focuses on leveraging herbal formulas to treat liver cancer. His professional endeavors at The University of Hong Kong underscore his commitment to advancing this field through innovative research and clinical applications.

 

📊🔬NOTABLE PUBLICATION:

 

  • Title: CRISPR/Cas9 screens unravel miR-3689a-3p regulating sorafenib resistance in hepatocellular carcinoma via suppressing CCS/SOD1-dependent mitochondrial oxidative stress
    Authors: Lu, Y., Chan, Y.-T., Wu, J., Feng, Y., Wang, N.
    Year: 2023

 

  • Title: Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC
    Authors: Chan, Y.-T., Wu, J., Lu, Y., Feng, Y., Wang, N.
    Journal: Molecular Cancer
    Year: 2024

 

  • Title: PARD3 drives tumorigenesis through activating Sonic Hedgehog signalling in tumour-initiating cells in liver cancer
    Authors: Wu, J., Tan, H.-Y., Chan, Y.-T., Feng, Y., Wang, N.
    Journal: Journal of Experimental and Clinical Cancer Research
    Year: 2024

 

  • Title: Updated Insights into Probiotics and Hepatobiliary Diseases
    Authors: Xu, X., Zhang, C., Tang, G., Wang, N., Feng, Y.
    Journal: Biomedicines
    Year: 2024

 

  • Title: Effects and mechanisms of anti-diabetic dietary natural products: an updated review
    Authors: Cheng, J., Li, J., Xiong, R.-G., Feng, Y., Gan, R.-Y.
    Journal: Food and Function
    Year: 2024